leadf
logo-loader
viewGenprex, Inc.

Genprex rakes in $8M in at-the-market stock offering

The gene therapy company sold 7.6 million shares of stock at a price of $1.05 per share

Moneybags changing hands
Genprex is developing a new approach to treating cancer, including its initial product candidate Oncoprex, which is an immunogene therapy for non-small cell lung cancer

Genprex Inc (NASDAQ:GNPX) announced an $8 million offering of stock through securities purchase agreements made with influential investors.  

The gene therapy company sold 7.6 million shares at a price of $1.05 per share, in accordance with Nasdaq rules governing registered direct offerings. 

READ: Genprex wins FDA Fast Track status for its Oncoprex therapy in combination with AstraZeneca's Tagrisso

Genprex, based in Austin, Texas and Cambridge, Massachusetts, plans to use the proceeds to advance its clinical programs in non-small cell lung cancer, as well as for working capital and general corporate purposes. 

The company is developing a new approach to treating cancer, including its initial product candidate Oncoprex, which is an immunogene therapy for non-small cell lung cancer.

Contact Andrew Kessel at andrew.kessel@proactiveinvestors.com 

Follow him on Twitter @andrew_kessel

Quick facts: Genprex, Inc.

Price: 3.36 USD

NASDAQ:GNPX
Market: NASDAQ
Market Cap: $130.61 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Genprex, Inc. named herein, including the promotion by the Company of Genprex, Inc. in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Genprex reveals slew of recent milestones as it plans for upcoming clinical...

Genprex Inc (NASDAQ:GNPX) CEO Rodney Varner talks to Proactive's Christine Corrado about the Texas-based biotechnology company's most recent updates. Namely, Varner says the firm has approved the generic name quaratusugene ozeplasmid, for its non-small cell lung cancer drug formerly known as...

on 07/02/2020

2 min read